All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub was proud to host a virtual Satellite Symposium on the management and treatment of patients with relapsed/refractory (R/R) lymphoma. Kieron Dunleavy, George Washington University Cancer Center, Washington, US, summarizes what he considers to be the feasible next steps for a patient with diffuse large B-cell lymphoma (DLBCL) following relapse to chimeric antigen receptor (CAR) T-cell therapy.
Satellite Symposium | Patient with R/R DLBCL— US perspective
He outlines recently approved agents and combination regimens, as well as therapies being evaluated in clinical trials. Kieron Dunleavy concludes with an emphasis on prognostic techniques, stressing the need for a biopsy to determine the patients CD19 expression profile. In terms of therapeutic approach, he suggests enrolling the patient onto a clinical trial evaluating novel bispecific antibodies.
Satellite Symposium | Patient with R/R DLBCL— US perspective
If you would like to download the slides from Kieron Dunleavy's presentation, click below.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?